Opportunities for Improving the Drug Development Process: Results from a Survey of Industry and the FDA

Ernst R. Berndt, Adrian H. B. Gottschalk and Matthew W. Strobeck

No 11425, NBER Working Papers from National Bureau of Economic Research, Inc

Abstract: In the United States, the Food and Drug Administration (FDA) agency is responsible for regulating the safety and efficacy of biopharmaceutical drug products. Furthermore, the FDA is tasked with speeding new medical innovations to market. These two missions create an inherent tension within the agency and between the agency and key stakeholders. Oftentimes, communications and interactions between regulated companies and the FDA suffer. The focus of this research is on the interactions between the FDA and the biopharmaceutical companies that perform drug R&D. To assess the current issues and state of communication and interaction between the FDA and industry, we carried out a survey of industry leadership in R&D and regulatory positions as well as senior leadership at the FDA who have responsibility for drug evaluation and oversight. Based on forty-nine industry and eight FDA interviews we conducted, we found that industry seeks additional structured and informal interactions with the FDA, especially during Phase II of development. Overall, industry placed greater value on additional communication than did the FDA. Furthermore, industry interviewees indicated that they were willing to pay PDUFA-like fees during clinical development to ensure that the FDA could hire additional, well-qualified staff to assist with protocol reviews and decision-making. Based on our survey and discussions, we uncovered several thematic opportunities to improve interactions between the FDA and industry and to reduce clinical development times: 1) develop metrics and goals at the FDA for clinical development times in exchange for PDUFA like fees; 2) establish an oversight board consisting of industry, agency officials, and premier external scientists (possibly at NIH or CDC) to evaluate and audit retrospectively completed and terminated drug projects; and 3) construct a knowledge database that can simultaneously protect proprietary data while allowing sponsor companies to understand safety issues and problems of previously developed/failed drug programs. While profound scientific and medical challenges face the FDA and industry, the first step to reducing development times and associated costs and facilitating innovation is to provide an efficient regulatory process that reduces unnecessary uncertainty and delays due to lack of communication and interaction.

JEL-codes: H11 I1 K23 (search for similar items in EconPapers)
Date: 2005-06
New Economics Papers: this item is included in nep-hea, nep-ino, nep-law and nep-pbe
Note: EH PR
References: Add references at CitEc
Citations:

Published as Berndt, Ernst R., Adrian H. B. Gottschalk, Matthew W. Strobeck. "Opportunities for Improving the Drug Development Process: Results from a Survey of Industry and the FDA." Innovation Policy and the Economy 6 (2006): 91-121.
Published as Opportunities for Improving the Drug Development Process: Results from a Survey of Industry and the FDA , Ernst R. Berndt, Adrian H. B. Gottschalk, Matthew W. Strobeck. in Innovation Policy and the Economy, Volume 6 , Jaffe, Lerner, and Stern. 2006

Downloads: (external link)
http://www.nber.org/papers/w11425.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nbr:nberwo:11425

Ordering information: This working paper can be ordered from
http://www.nber.org/papers/w11425

Access Statistics for this paper

More papers in NBER Working Papers from National Bureau of Economic Research, Inc National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.. Contact information at EDIRC.
Bibliographic data for series maintained by ().